The Biotech Capital Group

 PRESS RELEASE

For Immediate Release

Thomas Latino
The Biotech Capital Group


biotechcapital@gmx.com
http://biotechcapital.synthasite.com

The Biotech Capital Group initiates research coverage on NanoViricides, Inc, set to issue comprehensive research report tomorrow.

July, 23 2008 - Chicago, IL - The Biotech Capital Group, a Chicago based firm, announced today it has initiated research coverage on NanoViricides, Inc (OTCBB:NNVC) and will release a comprehensive research report on Thursday, July 24. Nanoviricides, Inc. is currently developing nano-technology based anti-viral therapeutics utilizing groundbreaking scientific research; combining the fields of nanotechnology, virology and immunology.

"The Biotech Capital Group is excited about the research NNVC is conducting. We believe NNVC is on the verge of revolutionizing how viruses are detected, treated and destroyed" stated Thomas Latino, President of the Biotech Capital Group. "NNVC's research is truly innovative and we are looking forward to hearing about NNVC's latest achievements." The research report will contain detailed analysis of the company's technology, business plan and drug development strategy. The report will contain several financial models as well as technical analysis of NNVC stock.

The Biotech Capital Group is a Chicago based firm specializing in securing venture capital and investment banking services for biotechnology companies. BCG also specializes in investor relations and serves as liaison between companies and the Securities and Exchange Commission.

The Biotech Capital Group does NOT receive compensation EXPLICITLY for research reports and NanoViricides, Inc DID NOT compensate The Biotech Capital Group for the research report.  However, The Biotech Capital Group has contracted with NanoViricides, Inc to assist in the raising of capital for the continuation of Nanoviricide's research and furthermore, BCG does NOT receive any monthly or yearly retainer fees as a result of this agreement.